Tenax Therapeutics Stock Price

-0.04 (-3.42%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 47,999
Bid Price 1.08
Ask Price 1.20
News (1)
Day High 1.19


52 Week Range


Day Low 1.11
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Tenax Therapeutics Inc TENX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.04 -3.42% 1.13 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.16 1.11 1.19 1.16 1.17
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
200 47,999 $ 1.15 $ 55,062 - 1.01 - 3.68
Last Trade Time Type Quantity Stock Price Currency
16:45:04 formt 167 $ 1.13 USD


Draw Mode:

Tenax Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 28.48M 25.21M 20.85M $ - $ - -1.39 -0.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 16.30%

more financials information »

Tenax Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TENX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.301.351.111.2273,729-0.17-13.08%
1 Month1.531.541.111.3382,995-0.40-26.14%
3 Months1.401.95941.111.52133,862-0.27-19.29%
6 Months2.022.301.111.72120,764-0.89-44.06%
1 Year1.123.681.012.071,685,0350.010.89%
3 Years1.875.120.251.86877,135-0.74-39.57%
5 Years39.0053.000.254.88705,820-37.87-97.1%

Tenax Therapeutics Description

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com.

Your Recent History
Tenax Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.